Field effectiveness of vaccination against tick-borne encephalitis

Vaccine

Volumn 25, Issue 43, 2007, Pages 7559-7567

  Heinz, Franz X ^a   Holzmann, Heidemarie ^a   Essl, Astrid ^b   Kundi, Michael ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Fessel GfK Institute of Health Care   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Tick borne encephalitis (TBE); Vaccination coverage; Vaccine effectiveness

Indexed keywords

TICK BORNE ENCEPHALITIS VACCINE;

ARTICLE; AUSTRIA; DRUG EFFICACY; GROUPS BY AGE; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TICK BORNE ENCEPHALITIS; VACCINATION;

ADOLESCENT; ADULT; ANIMALS; AUSTRIA; CHILD; CHILD, PRESCHOOL; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MIDDLE AGED; TREATMENT OUTCOME; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 34848839208     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.024     Document Type: Article

References (51)

1. Burke D.S., and Monath T.P. Flaviviruses. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., et al. (Eds). Fields virology. 4th ed. (2001), Lippincott, Williams & Wilkins, Philadelphia 1043-1126
2. Lindenbach B.D., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., et al. (Eds). Fields Virology. 4th ed. (2001), Lippincott, Williams & Wilkins, Philadelphia 991-1041
3. Dumpis U., Crook D., and Oksi J. Tick-borne encephalitis. Clin Infect Dis 28 4 (1999) 882-890
4. Suss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine 21 Suppl 1 (2003) S19-S35
5. Ecker M., Allison S.L., Meixner T., and Heinz F.X. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol 80 (1999) 179-185
6. Holzmann H., Vorobyova M.S., Ladyzhenskaya I.P., Ferenczi E., Kundi M., Kunz C., et al. Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes. Vaccine 10 5 (1992) 345-349
7. Gritsun T.S., Nuttall P.A., and Gould E.A. Tick-borne flaviviruses. Adv Virus Res 61 (2003) 317-371
8. Golovljova I., Vene S., Sjolander K.B., Vasilenko V., Plyusnin A., and Lundkvist A. Characterization of tick-borne encephalitis virus from Estonia. J Med Virol 74 4 (2004) 580-588
9. Jaaskelainen A.E., Tikkakoski T., Uzcategui N.Y., Alekseev A.N., Vaheri A., and Vapalahti O. Siberian subtype tickborne encephalitis virus, Finland. Emerg Infect Dis 12 10 (2006) 1568-1571
10. Mickiene A., Vene S., Golovljova I., Laiskonis A., Lindquist L., Plyusnin A., et al. Tick-borne encephalitis virus in Lithuania. Eur J Clin Microbiol Infect Dis 20 12 (2001) 886-888
11. The vector-borne human infections of Europe-their distribution and burden on public health. In: WHO Regional Office for Europe (WHO/EURO), Copenhagen, Denmark, 2004, pp. 37-53.
12. Ternovoi V.A., Kurzhukov G.P., Sokolov Y.V., Ivanov G.Y., Ivanisenko V.A., Loktev A.V., et al. Tick-borne encephalitis with hemorrhagic syndrome, Novosibirsk region, Russia, 1999. Emerg Infect Dis 9 6 (2003) 743-746
13. Korenberg E.I., and Kovalevskii Y.V. Main features of tick-borne encephalitis eco-epidemiology in Russia. Zentralbl Bakteriol 289 5-7 (1999) 525-539
14. Haglund M., and Gunther G. Tick-borne encephalitis-pathogenesis, clinical course and long-term follow-up. Vaccine 21 Suppl 1 (2003) S11-S18
15. Barrett P.N., Dorner F., Ehrlich H., and Plotkin S.A. Tick-borne encephalitis virus vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), Elsevier Inc., USA 1039-1055
16. Barrett P.N., Schober-Bendixen S., and Ehrlich H.J. History of TBE vaccines. Vaccine 21 Suppl 1 (2003) S41-S49
17. Heinz F.X., Kunz C., and Fauma H. Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation. J Med Virol 6 3 (1980) 213-221
18. Kunz C. TBE vaccination and the Austrian experience. Vaccine 21 Suppl 1 (2003) S50-S55
19. Kunz C., Heinz F.X., and Hofmann H. Immunogenicity and reactogenicity of a highly purified vaccine against tick-borne encephalitis. J Med Virol 6 2 (1980) 103-109
20. Harabacz I., Bock H., Jungst C., Klockmann U., Praus M., and Weber R. A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens. Vaccine 10 3 (1992) 145-150
21. Zent O., Hennig R., Banzhoff A., and Broker M. Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers. J Travel Med 12 2 (2005) 85-93
22. Kreil T.R., Burger I., Bachmann M., Fraiss S., and Eibl M.M. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 110 3 (1997) 358-361
23. Kreil T.R., and Eibl M.M. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol 71 4 (1997) 2921-2927
24. Kreil T.R., Maier E., Fraiss S., and Eibl M.M. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J Virol 72 4 (1998) 3076-3081
25. Tesh R.B., Arroyo J., Travassos Da Rosa A.P., Guzman H., Xiao S.Y., and Monath T.P. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 8 12 (2002) 1392-1397
26. Diamond M.S., Shrestha B., Marri A., Mahan D., and Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77 4 (2003) 2578-2586
27. Engle M.J., and Diamond M.S. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 77 24 (2003) 12941-12949
28. Ben-Nathan D., Lustig S., Tam G., Robinzon S., Segal S., and Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 188 1 (2003) 5-12
29. Hombach J., Solomon T., Kurane I., Jacobson J., and Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, September 2-3, 2004. Vaccine 23 45 (2005) 5205-5211
30. Jefferson T., Rivetti D., Di Pietrantonj C., Rivetti A., and Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2 (2007) CD001269
31. Chang M.H. Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations. J Clin Virol 36 Suppl 1 (2006) S45-S50
32. Chien Y.C., Jan C.F., Kuo H.S., and Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 28 (2006) 126-135
33. Fiore A.E., Wasley A., and Bell B.P. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-7 (2006) 1-23
34. Werzberger A., Mensch B., Nalin D.R., and Kuter B.J. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine 20 13-14 (2002) 1699-1701
35. Hoke C.H., Nisalak A., Sangawhipa N., Jatanasen S., Laorakapongse T., Innis B.L., et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319 10 (1988) 608-614
36. Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine 21 Suppl 1 (2003) S36-S40
37. Randolph S.E. Evidence that climate change has caused 'emergence' of tick-borne diseases in Europe?. Int J Med Microbiol 293 Suppl 37 (2004) 5-15
38. Randolph S.E., and Rogers D.J. Fragile transmission cycles of tick-borne encephalitis virus may be disrupted by predicted climate change. Proc Biol Sci 267 1454 (2000) 1741-1744
39. Gruver A.L., Hudson L.L., and Sempowski G.D. Immunosenescence of ageing. J Pathol 211 2 (2007) 144-156
40. Kovaiou R.D., Herndler-Brandstetter D., and Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Exp Rev Mol Med 9 3 (2007) 1-17
41. Hainz U., Jenewein B., Asch E., Pfeiffer K.P., Berger P., and Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 23 25 (2005) 3232-3235
42. Pawelec G. Immunity and ageing in man. Exp Gerontol 41 12 (2006) 1239-1242
43. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. Brain 122 Pt 11 (1999) 2067-2078
44. Kaiser R. Tick-borne encephalitis (TBE) in Germany and clinical course of the disease. Int J Med Microbiol 291 Suppl 33 (2002) 58-61
45. Pikelj F., Tomazic J., Maticic M., Socan M., and Muzlovic I. Severe forms of tick-borne meningoencephalitis in Slovenia. J Infect 31 1 (1995) 83-85
46. Rendi-Wagner P., Kundi M., Zent O., Banzhoff A., Jaehnig P., Stemberger R., et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine 23 4 (2004) 427-434
47. Rendi-Wagner P., Kundi M., Zent O., Dvorak G., Jaehnig P., Holzmann H., et al. Persistence of protective immunity following vaccination against tick-borne encephalitis-longer than expected?. Vaccine 22 21-22 (2004) 2743-2749
48. Rendi-Wagner P., Zent O., Jilg W., Plentz A., Beran J., and Kollaritsch H. Persistence of antibodies after vaccination against tick-borne encephalitis. Int J Med Microbiol 296 Suppl 40 (2006) 202-207
49. Kunz C. Tick-borne encephalitis in Europe. Acta Leidensia 60 2 (1992) 1-14
50. FSME. Risikogebiete in Deutschland. Epidemiologisches Bull. 2007;15:129-40.
51. Zeckenenzephalitis (FSME): weitere Zunahme der gemeldeten Fälle im 2006. In: Bulletin BAG 2007, Epi Notiz, p. 57-60 (www.bag.admin.ch).